Lipopeptide stimulation of MHC class I-restricted memory cytotoxic T lymphocytes from equine infectious anemia virus-infected horses.
The immunogenicity of equine infectious anemia virus (EIAV) Gag and Env equine leukocyte alloantigen (ELA)-A5.1, -A9, and -A1 restricted cytotoxic T lymphocyte (CTL) epitopes synthesized on multiple antigenic peptide (MAP) system coupled to tripalmitoyl-S-glycerylcysteine (P3C) was evaluated in vitro. P3C-MAP-peptide-stimulated peripheral blood mononuclear cells (PBMCs) from horses, chronically infected with EIAV, had memory CTL (CTLm) similar to that of PBMCs stimulated with either the minimal CTL epitopes, longer peptides containing the CTL epitopes, or EIAV. The stimulated CTL lysed EIAV-infected target cells and the percent specific lysis was dependent on the dose of P3C-MAP-peptide used to stimulate PBMCs in vitro and was peptide specific and ELA-A restricted. The results suggest that these P3C-MAP-peptides can be used as immunogens to stimulate primary immune responses in vivo.
Ridgely
Sherritta L
SL
Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA 99164, USA.
McGuire
Travis C
TC
D000595:Amino Acid Sequence; D000818:Animals; D000956:Antigens, Viral / Q000008:administration & dosage / Q000235:genetics; D003545:Cysteine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000276:immunology; D000939:Epitopes / Q000008:administration & dosage / Q000235:genetics; D004859:Equine Infectious Anemia / Q000276:immunology*; D015686:Gene Products, env / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006736:Horses; D007156:Immunologic Memory; D066298:In Vitro Techniques; D004860:Infectious Anemia Virus, Equine / Q000235:genetics / Q000276:immunology*; D008074:Lipoproteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D008969:Molecular Sequence Data; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology*; D014758:Viral Core Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D000956:Antigens, Viral; D000939:Epitopes; D015686:Gene Products, env; D015395:Histocompatibility Antigens Class I; D008074:Lipoproteins; D014758:Viral Core Proteins; C117895:equine infectious anemia virus, p26; C038837:tripalmitoyl cysteine; D003545:Cysteine